Pacific Biosciences Of California (PACB) EBIT (2010 - 2026)

Pacific Biosciences Of California has reported EBIT for 17 years, with the latest figure at -$44.6 million in Q2 2026.

• On a quarterly basis, EBIT rose 0.54% year-over-year to -$44.6 million in Q2 2026; TTM through Jun 2026 was -$133.0 million, a 80.74% increase from a year earlier, with the FY2025 full-year figure at -$553.9 million, down 16.77% from the prior year.
• EBIT was -$44.6 million for Q2 2026 at Pacific Biosciences Of California, down from -$8.4 million in the prior quarter.
• The five-year high for EBIT was -$8.4 million in Q1 2026, with the low at -$428.9 million in Q1 2025.
• Average EBIT over 5 years is -$95.7 million, with a median of -$76.1 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: EBIT tumbled 427.19% in 2025, then surged 98.05% in 2026.
• Over 5 years, EBIT stood at -$87.1 million in 2022, then declined by 0.53% to -$87.5 million in 2023, then slumped by 74.79% to -$153.0 million in 2024, then soared by 73.08% to -$41.2 million in 2025, then declined by 8.28% to -$44.6 million in 2026.
• The last three EBIT figures came in at -$44.6 million (Q2 2026), -$8.4 million (Q1 2026), and -$41.2 million (Q4 2025), per Business Quant data.